Thymalin
Also known as: Timalin · Thymus polypeptide extract
Research focus
Immune restoration; T-cell function in elderly and post-infection states.
US regulatory status
Not FDA-approved · Not compoundable
Evidence rating
Theoretical
Origin
Developed and studied by Khavinson's group beginning in the 1970s. Registered as a medicinal product in Russia since the 1980s for adjunct use in immune-compromised states. Not imported under FDA-authorized channels.
Plain-language summary
Thymalin is a polypeptide extract from calf thymus gland studied mostly in Russia as an immune-system support in older adults, patients recovering from infection, and selected post-surgical patients. It is a registered drug in Russia. In the United States it has no regulatory approval and is not legally compoundable. The peer-reviewed literature is largely Russian-language and was produced by the same research group that developed the product.
Claimed mechanism (as reported)
Russian and some Ukrainian literature describes Thymalin as a thymic peptide extract that modulates T-cell maturation, enhances cell-mediated immunity, and supports cytokine balance in immunosenescence. Detailed molecular mechanism is incompletely characterized because the product is a peptide mixture rather than a single defined molecule.
Evidence summary
Decades of Russian clinical use, with hundreds of published papers, most from the originating research group. A small number of cooperative publications with Western investigators exist. Trial methodology in the available literature generally predates modern Good Clinical Practice (GCP) standards.
What the research reports
Peptide immunomodulators in geriatric practice (review + cohort summaries)
Grade CKhavinson VKh, Kuznik BI et al. · Advances in Gerontology; Bulletin of Experimental Biology and Medicine · 2010–2014
Reported finding: Thymalin administration to elderly subjects was reported to normalize T-cell subset ratios, reduce inflammatory markers, and improve infection-related outcomes versus standard care.
Sample: Aggregate n>500 across studies
Methodology: C — multi-site Russian cohort data with partial blinding
Limitations: Most studies not double-blind; outcomes not always consistent with modern cytokine/immunophenotype panels; patient selection heterogeneous.
Thymalin adjunctive therapy in acute infection (multi-site observational series)
Grade CKuznik BI, Khavinson VKh et al. · Advances in Gerontology · 2020–2022
Reported finding: Authors reported shorter hospital stays and reduced inflammatory markers in elderly patients receiving Thymalin alongside standard-of-care treatment for viral respiratory infection.
Sample: n>100
Methodology: C — retrospective / observational cohort during pandemic conditions
Limitations: Non-randomized, confounded by concurrent therapy, unblinded assessment.
Administration reported in studies
Russian published protocols describe intramuscular injection of 5–10 mg/day for 5–10 days, repeated every 3–6 months in chronic immune-compromised cohorts. TPS reports this to describe research conditions only — this is not a dosing recommendation.
This section reports what published studies describe. It is not a dosing recommendation from TPS.
Safety record
No consistent signal of serious adverse events in published Russian clinical use over four decades. Cautionary note: the absence of modern GCP-standard reporting means the safety record is less precisely characterized than it would be for an FDA-approved biologic.
US legal status
Not FDA-approved. Not on the 503A compoundable bulk substances list. Not legally compoundable for human clinical use in the United States. Possession of an unapproved drug product imported for personal use is a gray area under FDA personal-import discretion and is not endorsed by TPS.
Open research questions
- ? Are the reported immune-restoration effects reproducible in randomized, placebo-controlled, GCP-compliant trials?
- ? What is the precise peptide composition of current Russian-manufactured Thymalin batches, and how does lot-to-lot variation affect outcomes?
- ? How would Thymalin perform versus established, FDA-approved immunomodulators in head-to-head comparison?
Get new bioregulator research as it publishes
Summaries of the Russian and English-language literature, bias-checked and plainly framed.
Subscribe Free →